So far, many investigators recognize human S100A8/A9 (h-S100A8/A9) as a useful biomarker for IBD, especially in its active stage (Meuwis et al., 2013; Kalla et al., 2016); however, it was clinically difficult to directly connect the fluctuation of h-S100A8/A9 with the disease activity of UC. This evidence concerns the gene S100A8 and inflammatory bowel disease.